|
MechanismANGPTL3 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanismfactor XIa inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
|
Drug Highest PhasePhase 2/3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 2 A Multicenter, Single Arm, Open Label Phase II Clinical Study Evaluating the Long-term Efficacy and Safety of SHR-1918 in Homozygous Familial Hypercholesterolemia Patients
A multicenter, single arm, open label phase II clinical study evaluating the long-term efficacy and safety of SHR-1918 in homozygous familial hypercholesterolemia patients
/ Not yet recruitingPhase 1 Safety, Tolerability and Pharmacokinetic Studies of Single and Multiple Administrations of HRS-8829 in Healthy Subjects
This study adopted a single-center, randomized, double-blind, placebo-controlled, dose-escalation design and was divided into two parts: single-dose dose-escalation (SAD) and multiple-dose dose-escalation (MAD)
/ Not yet recruitingPhase 1 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HRS-4029 Following a Single Dose in Healthy Subjects
The study is being conducted to evaluate the safety, tolerability and pharmacokinetics of HRS-4029 following a single intravenous dose administration in healthy subjects.
100 Clinical Results associated with Beijing Suncadia Pharmaceuticals Co., Ltd
0 Patents (Medical) associated with Beijing Suncadia Pharmaceuticals Co., Ltd
100 Deals associated with Beijing Suncadia Pharmaceuticals Co., Ltd
100 Translational Medicine associated with Beijing Suncadia Pharmaceuticals Co., Ltd